Portfolio company
ACHV
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This pharmaceutical company develops cytisinicline to treat nicotine dependence for individuals attempting to quit smoking or using e-cigarettes.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Blip
This company manufactures nicotine replacement therapies, such as gum and lozenges, for consumers who want to quit smoking or vaping.
HabitHalo
This company develops mobile applications and smart hardware devices to help individuals track, manage and reduce their nicotine consumption or quit vaping.
AQUILON PHARMACEUTICALS
The company develops inhaled medicines and nasal sprays for patients with asthma, chronic obstructive pulmonary disease and other respiratory conditions.
AKRO
This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.
PHVS
This company develops oral therapies to treat and prevent hereditary angioedema attacks for patients with rare diseases.
Smokeless World
This company develops artificial intelligence powered electronic cigarettes and software programmes to help smokers reduce nicotine intake and overcome addiction.
Chrono Therapeutics
This company develops wearable digital drug delivery devices and mobile applications that provide timed nicotine doses and behavioural support for people quitting smoking.
Miist Therapeutics
This company develops inhaled drug delivery devices providing rapid symptom relief for patients suffering from migraines or seeking smoking cessation.